In patients with non-small cell lung cancer (NSCLC) treated with gemcitabine-based therapy, the non-synonymous SLC28A1 variant c.1561G>A/T (p.Asp521Asn/Tyr, rs2242046) has been associated with increased myelotoxicity due to an increased gemcitabine absorption[120]. The gene discussed is SLC28A1; the disease is non-small cell lung carcinoma.